BioXcel Therapeutics (BTAI) Research & Development (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Research & Development of $3.0 million for Q1 2026, down 35.11% year-over-year from $4.6 million in Q1 2025, and down 55.9% quarter-over-quarter from $6.7 million in Q4 2025.
BioXcel Therapeutics (BTAI) Research & Development (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Research & Development history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Research & Development fell 35.11% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $28.7 million (up 21.47% YoY), while the FY2025 annual figure was $30.3 million, down 0.6% from the prior year.
- Research & Development for Q1 2026 stood at $3.0 million, down from $6.7 million in the prior quarter.
- The five-year high for Research & Development was $32.5 million in Q4 2022, with the low at $3.0 million in Q1 2026.
- The 5-year median for Research & Development is $10.3 million (2025), against an average of $14.1 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development jumped 159.15% in 2022, then plunged 74.0% in 2024.
- BioXcel Therapeutics' Research & Development stood at $32.5 million in 2022, then slumped by 69.4% to $9.9 million in 2023, then plunged by 40.6% to $5.9 million in 2024, then grew by 13.56% to $6.7 million in 2025, then sank by 55.9% to $3.0 million in 2026.
- Business Quant data shows BTAI's Research & Development at $3.0 million in Q1 2026, $6.7 million in Q4 2025, and $8.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.26 Mn | 24.26 Mn | 160,000.00 | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.16 Mn |
| Mar 31, 2026 | 2.96 Mn |
| Dec 31, 2025 | 6.70 Mn |
| Sep 30, 2025 | 8.74 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 5.90 Mn |
| Sep 30, 2024 | 5.10 Mn |
| Jun 30, 2024 | 8.03 Mn |
| Mar 31, 2024 | 11.40 Mn |
| Dec 31, 2023 | 9.93 Mn |
| Sep 30, 2023 | 19.62 Mn |
| Jun 30, 2023 | 26.97 Mn |
| Mar 31, 2023 | 27.80 Mn |
| Dec 31, 2022 | 32.46 Mn |
| Sep 30, 2022 | 22.06 Mn |
| Jun 30, 2022 | 17.91 Mn |
| Mar 31, 2022 | 18.56 Mn |
| Dec 31, 2021 | 12.53 Mn |
| Sep 30, 2021 | 11.93 Mn |